A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

Osteoporosis International

Volumn 12, Issue 2, 2001, Pages 140-151

  Cranney, A ^a   Guyatt, G ^b   Krolicki, N ^b   Welch, V ^a   Griffith, L ^b   Adachi, J D ^a   Shea, B ^a   Tugwell, P ^a   Wells, G ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; Bone density; Etidronate; Fractures; Meta analysis; Osteoporosis; Systematic reviews

Indexed keywords

CALCIUM; ETIDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; FEMALE; FEMUR NECK; FRACTURE; HUMAN; LUMBAR SPINE; MEDICAL INFORMATION; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

AGED; BONE DENSITY; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; SPINAL FRACTURES;

EID: 0035082837     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980170147     Document Type: Article

References (50)

1. How many women have osteoporosis now?
2. Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation
3. Current and projected rates of hip fractures in Canada
4. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada
5. Guidelines for diagnosis and management of osteoporosis
6. Bisphosphonates: Preclinical aspects and use in osteoporosis
7. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials
8. Developing optimal search strategies for detecting clinically sound studies in MEDLINE
9. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study
10. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
11. Publication bias: A brief review for clinicians
12. Empirical assessment of effect of publication bias on meta-analyses
13. Publication bias
14. The statistical basis of meta-analysis
15. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
16. Small sample considerations in combining 2 × 2 tables
17. Preliminary observations of a form of coherence therapy for osteoporosis
18. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime
19. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and disphosphonate EHDP: Protocol of Study I, Osteoporosis Trial Hannover
20. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: A clinical and bone histomorphometric study
21. The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate
22. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis
23. A randomized, double-blind comparison of residronate and etidronate in the treatment of Paget's disease of bone
24. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women
25. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis
26. Clinical experience with etidronate in osteoporosis
27. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis
28. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation
29. Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate
30. Effect of etidronate disodium on bone turnover following surgical menopause
31. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
32. Etidronate disodium in postmenopausal osteoporosis
33. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: Results of three years of treatment
34. Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study
35. Effect of intermittent cyclic etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
36. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: A four-year study
37. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
38. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: A prospective study
39. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year open therapy
40. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women
41. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo- controlled study and 1-year follow-up)
42. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo- controlled study
43. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy
44. Prevention of early postmenopausal bone loss with cyclical etidronate: A double-blind, placebo-controlled study
45. Contribution of vertebral deformities to chronic back pain
46. Pain and disability associated with new vertebral fractures and other spinal conditions
47. The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures
48. The impact of incident vertebral fracture of health related quality of life in established postmenopausal osteoporosis: Results from the Multiple Outcomes of Raloxifene Evaluation Study
49. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures